Design and Selection of Engineered Lytic Proteins With Staphylococcus aureus Decolonizing Activity

Staphylococcus aureus causes various infections in humans and animals, the skin being the principal reservoir of this pathogen. The widespread occurrence of methicillin-resistant S. aureus (MRSA) limits the elimination and treatment of this pathogen. Phage lytic proteins have been proven as efficient antimicrobials against S. aureus. Here, a set of 12 engineered proteins based on endolysins were conceptualized to select the most optimal following a stepwise funnel approach assessing parameters including turbidity reduction, minimum inhibitory concentration (MIC), time-kill curves, and antibiofilm assays, as well as testing their stability in a broad range of storage conditions (pH, temperature, and ionic strength). The engineered phage lysins LysRODI Delta Ami and ClyRODI-H5 showed the highest specific lytic activity (5 to 50 times higher than the rest), exhibited a shelf-life up to 6 months and remained stable at temperatures up to 50 degrees C and in a pH range from 3 to 9. LysRODI Delta Ami showed the lower MIC values against all staphylococcal strains tested. Both proteins were able to kill 6 log units of the strain S. aureus Sa9 within 5 min and could remove preformed biofilms (76 and 65%, respectively). Moreover, LysRODI Delta Ami could prevent biofilm formation at low protein concentrations (0.15-0.6 mu M). Due to its enhanced antibiofilm properties, LysRODI Delta Ami was selected to effectively remove S. aureus contamination in both intact and disrupted keratinocyte monolayers. Notably, this protein did not demonstrate any toxicity toward human keratinocytes, even at high concentrations (22.1 mu M). Finally, a pig skin ex vivo model was used to evaluate treatment of artificially contaminated pig skin using LysRODI Delta Ami (16.5 mu g/cm(2)). Following an early reduction of S. aureus, a second dose of protein completely eradicated S. aureus. Overall, our results suggest that LysRODI Delta Ami is a suitable candidate as antimicrobial agent to prevent and treat staphylococcal skin infections.

Automated summary

A series of engineered proteins based on endolysins were designed and screened, with LysRODI Delta Ami identified as having high lytic activity, stability, and antimicrobial properties to effectively prevent and treat Staphylococcus aureus skin infections.